[go: up one dir, main page]

MX2018002447A - Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lupica. - Google Patents

Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lupica.

Info

Publication number
MX2018002447A
MX2018002447A MX2018002447A MX2018002447A MX2018002447A MX 2018002447 A MX2018002447 A MX 2018002447A MX 2018002447 A MX2018002447 A MX 2018002447A MX 2018002447 A MX2018002447 A MX 2018002447A MX 2018002447 A MX2018002447 A MX 2018002447A
Authority
MX
Mexico
Prior art keywords
antibodies
treatment
lupus nephritis
therapeutic
prevention
Prior art date
Application number
MX2018002447A
Other languages
English (en)
Other versions
MX390653B (es
Inventor
Henry Nabozny Gerald
Ronald BRODEUR Scott
Ramanujam Meera
Scholl Paul
b freeman Thomas
Steffgen Juergen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2018002447A publication Critical patent/MX2018002447A/es
Publication of MX390653B publication Critical patent/MX390653B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos anti-CD40 antagonistas humanizados novedosos y métodos terapéuticos y diagnósticos y composiciones para el uso de estos para el tratamiento y/o prevención de nefritis lúpica.
MX2018002447A 2015-09-01 2016-08-31 Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica. MX390653B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Publications (2)

Publication Number Publication Date
MX2018002447A true MX2018002447A (es) 2018-06-15
MX390653B MX390653B (es) 2025-03-21

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002447A MX390653B (es) 2015-09-01 2016-08-31 Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica.

Country Status (16)

Country Link
US (3) US20170058038A1 (es)
EP (1) EP3344655B1 (es)
JP (2) JP2018529661A (es)
KR (1) KR20180039172A (es)
CN (1) CN107922501A (es)
AU (1) AU2016317028B2 (es)
BR (1) BR112018001907A2 (es)
CA (1) CA2993996A1 (es)
CL (1) CL2018000317A1 (es)
DK (1) DK3344655T5 (es)
ES (1) ES2969968T3 (es)
HU (1) HUE063528T2 (es)
MX (1) MX390653B (es)
PH (1) PH12018500445B1 (es)
PL (1) PL3344655T3 (es)
WO (1) WO2017040566A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
KR20240149979A (ko) * 2017-05-25 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
AU2019291890A1 (en) * 2018-06-29 2020-12-17 Boehringer Ingelheim International Gmbh Anti-CD40 antibodies for use in treating autoimmune disease
US20240254248A1 (en) * 2018-11-30 2024-08-01 Jiangsu Hengrui Medicine Co., Ltd. Cd40 antibody pharmaceutical composition and use thereof
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DE69315847T2 (de) 1992-08-21 1998-06-25 Genentech Inc Verfahren zur behandlung einer durch lfa-1 vermittelten störung
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
MXPA06012430A (es) * 2004-04-27 2007-04-19 Novartis Vaccines & Diagnostic Anticuerpos monoclonales antagonistas anti-cd40 y metodos para su uso.
CA2609269C (en) * 2005-05-26 2014-08-05 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
HUE049849T2 (hu) * 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
US8778345B2 (en) * 2011-04-29 2014-07-15 Apexigen, Inc. Anti-CD40 antibodies
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
HUE063528T2 (hu) 2024-01-28
PH12018500445A1 (en) 2018-09-10
ES2969968T3 (es) 2024-05-23
PL3344655T3 (pl) 2024-02-19
JP2018529661A (ja) 2018-10-11
PH12018500445B1 (en) 2022-08-10
WO2017040566A1 (en) 2017-03-09
US20230265203A1 (en) 2023-08-24
BR112018001907A2 (pt) 2018-09-25
CA2993996A1 (en) 2017-03-09
DK3344655T3 (da) 2023-10-09
CL2018000317A1 (es) 2018-07-20
EP3344655A1 (en) 2018-07-11
US20170058038A1 (en) 2017-03-02
KR20180039172A (ko) 2018-04-17
AU2016317028A1 (en) 2018-02-22
AU2016317028B2 (en) 2021-09-09
MX390653B (es) 2025-03-21
US20190177420A1 (en) 2019-06-13
CN107922501A (zh) 2018-04-17
EP3344655B1 (en) 2023-07-26
DK3344655T5 (da) 2024-10-07
JP2021185169A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
MX2018002447A (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lupica.
CL2018000128A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
EA201691541A1 (ru) Новые анти-baff антитела
EA201691974A1 (ru) Антитела против ox40 и способы их применения
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
MX2017010864A (es) Anticuerpos contra tau y sus usos.
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
CL2020003348A1 (es) Anticuerpos anti–cd40 para su uso en el tratamiento de enfermedades autoinmunes
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
PL3573620T3 (pl) Kompozycje do leczenia nadciśnienia
PH12019502694A1 (en) Anti-trkb antibodies
DK3638293T3 (da) Sammensætninger til behandling af cancer
ZA201907096B (en) Methods of using drift reduction adjuvant compositions
IL284327A (en) Compositions and methods for inhibiting hmgb1 expression
EA201691632A1 (ru) Пиразины в качестве модуляторов gpr6
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
GB201810746D0 (en) Use of sclerostin antagonist
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний
KR101912544B9 (ko) 어큐빈을 포함하는 신경정신 질환의 예방 또는 치료용 조성물